What does durvalumab/Infinifer injection do?

Durvalumab/Infinifer (Durvalumab) is a PD-L1 inhibitor that occupies an important position in global tumor immunotherapy. Its core function is to block the combination of PD-L1 and PD-1 , allowing the suppressed T cells to re-recognize tumor cells and achieve sustained anti-tumor activity. This mechanism is different from traditional chemotherapy, and its characteristics are closer to the regulation method of the body's natural immune system. Because of this, durvalumab has gradually become a key drug in the treatment of various solid tumors, especially in the field of lung cancer treatment.

Currently, one of its most important indications is for the consolidation treatment of unresectable Stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy. The guidelines believe that in patients at this stage, the tumor burden has decreased but there are still small residual cells, so a strategy that can "long-term control" is needed, and immune maintenance just fills this gap. Immobilumab prolongs disease stabilization, improves progression-free survival, and allows some patients to maintain remission over long-term follow-up. Many clinical observations have also found that its application after radiotherapy and chemotherapy is more likely to stimulate immune memory and make the treatment effect more lasting.

In addition to lung cancer, durvalumab has also been approved for use in small cell lung cancer, biliary tract cancer and other fields. Small cell lung cancer itself progresses rapidly, and the addition of immunotherapy has brought new treatment combinations to allow the initial response to chemotherapy to be maintained longer. In biliary tract tumors, it is often used in combination with chemotherapy, making the overall treatment strategy more scalable. Patients can often observe changes in tumor biological behavior after use, manifested as slowing down the course of the disease or alleviating symptoms.

Judging from the treatment experience, as an immune drug, durvalumab is administered by intravenous injection with a relatively fixed cycle, allowing patients to manage treatment regularly. Although immune-related adverse reactions require attention, most can be controlled through early identification and treatment.

Reference materials: https://www.imfinzi.com/